Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients

1 Jan 2016

Abstract excerpt

OBJECTIVE: This study investigated whether pyrosequencing can be used to determine the methylation status of the MGMT promoter as a clinical biomarker using relatively old archival tissue samples of glioblastoma. We also examined other prognostic factors for survival of glioblastoma patients. METHODS: The available study set included formalin-fixed paraffin-embedded (FFPE) tissue from 104 patients at two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26885283
DOI: 10.3340/jkns.2016.59.1.26

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma PatientsPMID 26885283Read ↗

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRSemantic proximity Read ↗

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastomaSemantic proximity Read ↗

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity Read ↗

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastomaSemantic proximity Read ↗

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma MultiformeSemantic proximity Read ↗

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudySemantic proximity Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastomaSemantic proximity Read ↗

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patientsSemantic proximity Read ↗

MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in GlioblastomasSemantic proximity Read ↗

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.